eli lilly glp-1 news FDA just approved orforglipron (Foundayo), Lilly's oral receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Lilly GLP-1 pill shows promising

Don Fishers leadership and over 40 years of clinical expertise, we offer carefully selected integrative treatments that blend bioidentical hormone therapy , IV nutrient support , functional medicine strategies , and regenerative protocols

This is often the first sign the therapy is working

Akkermansia muciniphila and Bifidobacterium bifidum Prevent NAFLD by Regulating FXR Expression and Gut Microbiota

Griffin, M

Especially under ischemiareperfusion conditions, reducing the level of acylcarnitine has a significant effect on the energy metabolism of the heart and the maturity and proliferation of cardiomyocytes because reducing the utilization of fatty acids and increasing the reliance on glucose oxidation as an energy source can promote the recovery of myocardial function at a lower rate of oxygen consumption